Friday, July 10, 2026

Drug profile · INN

troriluzole

troriluzole (DAZLUMA) is an FDA-listed pharmaceutical active ingredient.

EMA: application withdrawn Nervous system (N07) N07XX
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — troriluzole
Class
Nervous system (N07)
Route
Patents
0
Programs
3
Data quality
0.83

Quick answer

troriluzole (DAZLUMA) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN troriluzole
Brand DAZLUMA
Therapeutic class Nervous system (N07)
ATC code N07XX

Approval history

Authority Status Date
EMA application withdrawn

Pipeline programs

  1. BHV4157-303 Phase 3 · Anaxis Pharma · Obsessive Compulsive Disorder
  2. GCAR-7213 Phase 3 · Adaptive Biotechnologies · Oncology - Glioblastoma (GBM)
  3. Troriluzole, Troriluzole Phase 3 · Anaxis Pharma · Obsessive Compulsive Disorder

Related & competitor drugs

  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. brivaracetam Nervous system (N03)
  4. bupivacaine Nervous system (N01)
  5. buprenorphine Nervous system (N07)
  6. caffeine citrate Nervous system (N06)

Frequently asked questions

What is troriluzole?

troriluzole (DAZLUMA) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for troriluzole?

DAZLUMA is a marketed brand name for troriluzole. Check FDA Drugs@FDA for the current US label holder and prescribing information.